ε2 Allele and ε2-involved Genotypes (ε2/ε2, ε2/ε3, and ε2/ε4) May Confer the Association of APOE Genetic Polymorphism with Risks of Nephropathy in Type 2 Diabetes: a Meta-analysis

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2020 Jun 15

PMID 32534589

Citations 2

Authors

Jikang Shi

Zhaorui Cheng

Shuang Qiu

Heran Cui

Yulu Gu

Qian Zhao

Yaxuan Ren

He Zhang

Helin Sun

Yunkai Liu

Yong Li

Yichun Qiao

Yueyang Hu

Yawen Liu

Yi Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Diabetic nephropathy (DN) contributes to end-stage renal failure. Microvascular injury resulted from reactive oxygen species is implicated in the pathogenesis of DN. Genetic polymorphism of Apolipoprotein E (APOE) influences the antioxidative properties of the protein. The relationship of APOE polymorphism with the risks of nephropathy in type 2 diabetes (T2DN) remains elusive.

Methods: An up-to-date meta-analysis was conducted on the basis of studies selected from PubMed, WanFang database, Embase, Vip database, Web of Science, Scopus, and CNKI database.

Results: A total of 33 studies conferring 3266 cases and 3259 controls were selected on the basis of criteria of inclusion and exclusion in this meta-analysis. For APOE alleles, the pooled odds ratio (OR) of ε2 vs. ε3 was 1.89 (95% confidence intervals [95% CI]: 1.49-2.38, P < 0.0001). With regard to APOE genotypes, ε2/ε2, ε2/ε3, and ε2/ε4 increased the risk of T2DN (ε2/ε2 vs. ε3/ε3: OR = 2.32, 95% CI: 1.52-3.56, P = 0.0001; ε2/ε3 vs. ε3/ε3: OR = 1.97, 95% CI: 1.50-2.59, P<0.0001; ε2/ε4 vs. ε3/ε3: OR = 1.69, 95% CI: 1.18-2.44, P = 0.0046).

Conclusions: This meta-analysis found that the APOE ε2 allele and the ε2-involved genotypes (ε2/ε2, ε2/ε3, and ε2/ε4) are the risk factors of T2DN.

Citing Articles

The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis.

Taurbekova B, Mukhtarova K, Salpynov Z, Atageldiyeva K, Sarria-Santamera A BMC Nephrol. 2024; 25(1):436.

PMID: 39614174 PMC: 11607899. DOI: 10.1186/s12882-024-03859-6.

HDL and chronic kidney disease.

Pavanello C, Ossoli A Atheroscler Plus. 2023; 52:9-17.

PMID: 37193017 PMC: 10182177. DOI: 10.1016/j.athplu.2023.04.001.

References

Guan J, Zhao H, Baum L, Sui Y, He L, Wong H . Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation. Nephrol Dial Transplant. 2009; 24(6):1889-95. DOI: 10.1093/ndt/gfn734. View

Li Y, Tang K, Zhang Z, Zhang M, Zeng Z, He Z . Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep. 2010; 38(5):3243-52. DOI: 10.1007/s11033-010-9999-z. View

Liu C, Liu C, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9(2):106-18. PMC: 3726719. DOI: 10.1038/nrneurol.2012.263. View

Ng M, Baum L, So W, Lam V, Wang Y, Poon E . Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet. 2006; 70(1):20-8. DOI: 10.1111/j.1399-0004.2006.00628.x. View

Kwon M, Rhee S, Chon S, Oh S, Woo J, Kim S . Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2007; 77 Suppl 1:S228-32. DOI: 10.1016/j.diabres.2007.03.009. View

Jiang Y, Ma L, Han C, Liu Q, Cong X, Xu Y . Effects of Apolipoprotein E Isoforms in Diabetic Nephropathy of Chinese Type 2 Diabetic Patients. J Diabetes Res. 2017; 2017:3560920. PMC: 5343254. DOI: 10.1155/2017/3560920. View

Beisswenger P, Drummond K, Nelson R, Howell S, Szwergold B, Mauer M . Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes. 2005; 54(11):3274-81. DOI: 10.2337/diabetes.54.11.3274. View

Reis K, Ayerden Ebinc F, Koc E, Demirci H, Erten Y, Guz G . Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail. 2011; 33(5):469-74. DOI: 10.3109/0886022X.2011.568133. View

Miyata M, Smith J . Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996; 14(1):55-61. DOI: 10.1038/ng0996-55. View

10.

Munafo M, Flint J . Meta-analysis of genetic association studies. Trends Genet. 2004; 20(9):439-44. DOI: 10.1016/j.tig.2004.06.014. View

11.

Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K . The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003; 14(2):311-6. DOI: 10.1097/01.asn.0000045048.71975.fc. View

12.

Araki S . APOE polymorphism and diabetic nephropathy. Clin Exp Nephrol. 2013; 18(2):230-3. DOI: 10.1007/s10157-013-0862-0. View

13.

Xiang G, Xia B, He Y . [The relationship of Apo E2 and renal insufficiency lipid levels in NIDDM]. Zhonghua Yi Xue Za Zhi. 2001; 79(5):339-41. View

14.

Miranda-Diaz A, Pazarin-Villasenor L, Yanowsky-Escatell F, Andrade-Sierra J . Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. J Diabetes Res. 2016; 2016:7047238. PMC: 4971321. DOI: 10.1155/2016/7047238. View

15.

Zhang Y, Ma K, Liu J, Wu Y, Hu Z, Liu L . Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab. 2015; 308(12):E1140-8. DOI: 10.1152/ajpendo.00591.2014. View

16.

Wei L, Xiao Y, Li L, Xiong X, Han Y, Zhu X . The Susceptibility Genes in Diabetic Nephropathy. Kidney Dis (Basel). 2018; 4(4):226-237. PMC: 6276750. DOI: 10.1159/000492633. View

17.

Dong L, Parkin S, Trakhanov S, Rupp B, Simmons T, Arnold K . Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol. 1996; 3(8):718-22. DOI: 10.1038/nsb0896-718. View

18.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

19.

Gross J, de Azevedo M, Silveiro S, Canani L, Caramori M, Zelmanovitz T . Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2004; 28(1):164-76. DOI: 10.2337/diacare.28.1.164. View

20.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View